Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection

Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infection (ABSSSI) caused by Gram-positive bacteria in the United States, Europe, and other countries. In this multicenter, double-blind, phase 3 study, 598 adult ABSSSI patients in China, Taiwan, the Philip...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Antimicrob Agents Chemother
Päätekijät: Lv, Xiaoju, Alder, Jeff, Li, Li, O’Riordan, William, Rybak, Michael J., Ye, Hui, Zhang, Ruiping, Zhang, Zhongqi, Zhu, Xu, Wilcox, Mark H.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2019
Aiheet:
Clinical Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6591607/
https://ncbi.nlm.nih.gov/pubmed/30988146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02252-18
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia